The myth of the DSM “Bible” is debunked: “at best, [the DSM is] a dictionary, creating a set of labels and defining each. . . . Continue reading →
TIME Psychiatrist Contends the Field Is ‘Committing Professional Suicide’ Psychiatry — and medicine in general — has a dangerously close relationship with the pharmaceutical industry Maia Szalavitz | @maiasz | October 5, 2012 | British psychiatrist and Big Pharma gadfly David Healy . . . Continue reading →
The latest area of controversy focuses on the proposed revision of the definition "behavioral addiction disorder" extending the addiction diagnosis to include drug, alcohol and gambling. It is estimated that the change would expand the number of people labeled as "addicts" by 20 to 30 million who would be entitled to treatment and disability payments costing taxpayers many hundreds of millions of dollars. Continue reading →
At a minimum, the practice of responsible medicine requires that physicians who prescribe drugs whose known severe adverse side effects are likely to cause their patients irreversible harm, requires that those physicians follow monitoring guidelines to ensure their patients’ safety.
On Friday, April 6, the FDA approved another of Eli Lilly’s "breakthroughs" whose clinical value is questionable (at best). Continue reading →
The primary promoters–inventors, one might say– of diagnosing children with "bipolar" disorder, who for over a decade, aggressively promoted the biopolar diagnosis and use of antipsychotics in children, were disciplined by Harvard University and its affiliated Massachusetts General Hospital.
An audit by Daniel Levinson, Inspector General of DHHS, confirms what has already been documented: that antipsychotics are widely misprescribed for unapproved uses and taxpayers are saddled with the high cost through Medicaid and Medicare. Continue reading →
Johnson & Johnson officilas made a business decision to decieve doctors by lying about the diabetes risk: “how much commercial liability would we incur if we sent a similar letter about Risperdal”? Continue reading →
New FDA antipsychotic Warnings: "The symptoms of EPS and withdrawal in newborns may include agitation, abnormally increased or decreased muscle tone, tremor, sleepiness, severe difficulty breathing, and difficulty in feeding." Continue reading →
The excerpts from The New Yorker (below) may be read as a companion piece to the Atlantic article profiling Dr. John Ioannidis. However, the opening example that Lehrer uses to make the point that initial impressive positive research findings often weaken . . . Continue reading →